The study, published in Holistic Integrative Oncology, enrolled 108 women between November 2022 and June 2023, of whom 98 completed the protocol, with 49 assigned to each arm. To be eligible, patients had to be between 18 and 65 years old, have unilateral upper-extremity lymphedema defined as a circumference difference of at least two centimeters between the affected and healthy limbs, and have finished adjuvant chemotherapy and radiotherapy. Those with serious cardiopulmonary, orthopedic, neurologic, cognitive, or emotional disorders, metastatic cancer, or active infection were excluded. Randomization was performed by a blinded researcher using computer-generated numbers, with allocation concealed in sealed, sequentially numbered opaque envelopes, and all outcome assessments were carried out by an assessor who did not know which group each patient belonged to.

The intervention itself was a graduated, eight-week program delivered twice a day, five days a week, in small supervised groups of five to six women. Each session lasted roughly twenty minutes, split evenly between aerobic-style mobility work and resistance exercise using adjustable dumbbells. The resistance component included seated rows, latissimus dorsi pulldowns, one-arm bent-over rows, biceps curls, bench presses, and triceps extensions, performed in two to three sets of eight to twelve repetitions. Crucially, the load was individualized: each participant underwent a one-repetition maximum test before starting, then trained at just 20 percent of that maximum for the first two weeks, rising to 60 percent in weeks five and six and 80 percent in the final fortnight, with the absolute weight capped at 2.5 kilograms. Throughout, participants kept compression bandages on, in line with guideline recommendations that compression be worn during moderate resistance exercise at home.

The control group received standard complex decongestive physiotherapy, the internationally recognized gold standard that combines manual lymphatic drainage, compression therapy, skin care, and functional exercise. In the first month, these patients attended hospital-based sessions once a day, five days a week; in the second month, they self-managed at home with twenty minutes of aerobic exercise twice daily. What they did not receive was the progressive resistance component, allowing the trial to isolate the added value of weight training on top of conventional care. Adherence was tracked through electronic logs completed by physiotherapists, with high adherence defined as attending at least 80 percent of offered sessions, and participants reported their exercise through an internet follow-up platform with online access to therapists.

The primary outcome was limb circumference, measured at standardized anatomical landmarks: the midpoint of the ulnar styloid process, points 10, 20, 30, and 40 centimeters above it, and the axillary root. After eight weeks, the mean difference in circumference between the healthy and affected sides fell significantly in the intervention group, while the control group showed no significant change. The effect was most pronounced at the 10-centimeter and 20-centimeter marks above the elbow crease, where the between-group differences reached statistical significance. Upper limb function, assessed with the Disabilities of the Arm, Shoulder and Hand questionnaire and digital goniometer measurements of shoulder range of motion, did not differ significantly between the groups, a result the authors attribute at least in part to the modest sample size.

Perhaps the most intriguing finding concerned the mind rather than the muscle. Baseline anxiety, measured with the seven-item Generalized Anxiety Disorder scale, was comparable between groups, but after two months the intervention group’s anxiety scores were significantly lower than those of the controls. Depression, measured with the nine-item Patient Health Questionnaire, and quality of life, measured with the 36-item Functional Assessment of Cancer Therapy-Breast instrument, showed no statistically significant differences, although quality-of-life scores trended slightly higher in the exercising group. The authors suggest the absence of significance on those secondary measures may reflect the short eight-week window, which may simply have been too brief for broader psychosocial benefits to register on validated scales.

The physiological rationale for why lifting light weights could drain a swollen arm rests on what the researchers describe as a dual pump mechanism. Lymphatic vessels normally move fluid through their own rhythmic, autonomic contractions, but in lymphedema, valve insufficiency and damage to the muscular wall of the lymphatics impair this intrinsic transport, leaving skeletal muscle contraction as the dominant force pushing lymph back toward the torso. Breast cancer surgery damages chest wall and upper limb muscles, and scar tissue contracture can stiffen the shoulder, weakening this so-called muscle pump. Resistance training rebuilds that pump, while the flexion and extension of the joints themselves stimulates lymph nodes and vessels in what the authors call a joint pump, together promoting lymphatic return and reducing fluid accumulation. Compression garments worn during exercise provide the external pressure gradient that keeps newly mobilized fluid from pooling again distally.

The anxiety finding has a plausible neuroendocrine explanation as well. Anxiety is thought to arise, at least in part, from dysregulation of the hypothalamic-pituitary-adrenal axis, the body’s central stress system, producing hypervigilance and sympathetic overdrive. Resistance exercise acutely elevates testosterone and cortisol concentrations and, over weeks of training, appears to modulate this axis, offering a mechanistic bridge between mechanical work in the gym and measurable relief of psychological distress. The authors note that prior trials, including one in breast cancer patients receiving chemotherapy, failed to detect an anxiolytic effect of resistance training, and they caution that differences in populations and assessment tools mean the psychological benefits in lymphedema patients still require confirmation in larger studies.

The trial’s authors are candid about its limitations. The sample was small, the follow-up was short, and the study was conducted at a single center, all of which constrain the generalizability of the results and may explain why functional status and quality of life did not reach significance. Missing data were excluded from analysis, and the statistical thresholds were conventional, with significance set at P less than 0.05. Still, the direction of the findings aligns with a growing body of evidence: systematic reviews and meta-analyses have concluded that resistance exercise is safe for lymphedema patients, improves muscle strength and physical function, and does not trigger or worsen the condition, overturning decades of advice that told survivors to baby their affected arms.

The broader implications extend beyond swelling. Epidemiological research has linked resistance training at least once a week to a 33 percent reduction in mortality risk among breast cancer survivors, and earlier work by members of this research community showed that a twice-weekly, slowly progressive weight training program halved the incidence of clinical events requiring medical care for lymphedema, even if it did not reduce arm swelling itself. What the Tianjin trial adds is the suggestion that, when paired with compression, supervised progressive loading may actually reverse some of the circumference difference that defines the disease. For a condition long considered incurable and managed mainly through meticulous maintenance, the message to survivors is quietly radical: the affected arm is not fragile, and carefully dosed strength training, done under professional supervision with proper compression, may be one of the most effective tools available for taking back both the limb and the peace of mind that cancer treatment so often takes away.

Subject of Research: Resistance exercise and compression garment therapy for breast cancer-related lymphedema

Article Title: Effects of resistance exercise and compression garments in the management of breast cancer-related lymphedema: a randomized controlled trial

Article References: Zhu, M., Li, M., Li, J., Wu, P., Qiang, W., & Wang, Y. (2026). Effects of resistance exercise and compression garments in the management of breast cancer-related lymphedema: a randomized controlled trial. Holistic Integrative Oncology, 5(1), Article 25. https://doi.org/10.1007/s44178-026-00231-6

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00231-6

Keywords: breast cancer, lymphedema, resistance exercise, compression garments, randomized controlled trial, cancer rehabilitation, arm circumference, anxiety, quality of life, complex decongestive therapy, cancer survivorship, exercise oncology

The core of the authors’ argument is that losing lean mass is not the same thing as losing functional muscle. When any person loses weight, whether through diet, surgery, or medication, the body sheds both fat and lean tissue because a lighter body simply demands less structural and metabolic support. A recent meta-analysis cited in the perspective found that lean mass accounted for roughly 25 to 39 percent of the total weight lost with incretin-based therapies, a proportion broadly comparable to the 26.2 percent observed with conventional lifestyle interventions. In other words, the fraction of weight loss coming from lean tissue during pharmacotherapy looks remarkably similar to what happens when patients lose weight the old-fashioned way, suggesting that the phenomenon reflects physiological body composition remodeling rather than a drug-specific pathology.

Real-world comparative data strengthen this interpretation considerably. In a cohort of 3,066 individuals, fat-free mass decreased by 11.7 percent after bariatric surgery but by only 3.3 percent during treatment with semaglutide or tirzepatide over 24 months. Meanwhile, fat mass fell far more dramatically, by 49.7 percent in the surgical group and 18.0 percent in the medication group. Crucially, in both groups the ratio of fat-free mass to fat mass improved, meaning patients ended up with a more favorable body composition than they started with. The authors contend that this pattern, in which adipose tissue declines disproportionately while most lean tissue is preserved, is difficult to reconcile with the notion of treatment-induced muscle wasting, although they acknowledge that a treatment-specific contribution cannot be entirely excluded.

Body composition sub-studies from the major clinical trial programs reinforce the point. In the STEP trials of semaglutide and the SURMOUNT program of tirzepatide, investigators documented marked reductions in total fat mass alongside preservation of most lean mass, yielding a net improvement in the lean-to-fat mass ratio despite modest absolute declines in lean tissue. Similar findings have emerged with oral semaglutide in people with type 2 diabetes, where fat mass declined significantly while skeletal muscle index and lean body mass remained largely unchanged. Taken together, these data suggest that incretin therapies preferentially strip away the tissue that is causing harm while leaving the metabolically active machinery of muscle largely intact.

Perhaps the most provocative element of the perspective is its argument that obesity itself damages muscle quality, so that weight loss may actually improve the muscle that remains. Excess adiposity promotes the accumulation of fat within muscle fibers, chronic low-grade systemic inflammation, mitochondrial dysfunction, and reduced contractile efficiency, producing muscle that is quantitatively larger but functionally inferior. Intentional weight loss appears to reverse several of these abnormalities: even as lean mass declines modestly, reductions in intramuscular lipid infiltration and inflammation, together with improvements in oxidative capacity, may enhance the functional quality of skeletal muscle. The authors invoke a memorable formulation to capture this idea: a smaller muscle is not necessarily a weaker muscle, and may in fact be metabolically healthier and more efficient than the enlarged, fat-infiltrated muscle it replaces.

The strongest evidence against the sarcopenia hypothesis comes from measurements of what muscles actually do. Across obesity trials, incretin therapy has consistently improved exercise capacity, physical performance, and mobility rather than degrading them. Multiple STEP studies demonstrated meaningful improvements in physical functioning and obesity-specific quality of life following semaglutide treatment, outcomes that are difficult to square with clinically relevant muscle loss, which would be expected to impair rather than enhance function. Evidence from bariatric surgery points in the same direction: despite substantial reductions in lean body mass during the first postoperative year, relative muscle strength, gait speed, chair-stand performance, and overall physical function consistently improve, changes long recognized as reflecting favorable physiological remodeling. Subgroup analyses of the major obesity trials have also shown comparable efficacy and safety of incretin therapies in participants aged 65 and older compared with younger adults, supporting their use in appropriately selected older patients.

None of this means the field can afford complacency, and the authors are careful to delineate who remains genuinely at risk. Sarcopenic obesity, the coexistence of excess adiposity with impaired muscle quantity, quality, and function, is a well-recognized clinical entity associated with frailty, disability, hospitalization, cardiometabolic complications, and increased mortality, and current consensus definitions emphasize function rather than mass alone. Older adults and individuals with pre-existing sarcopenia or frailty, low muscle strength, chronic inflammatory, kidney, or cardiovascular disease, prolonged physical inactivity, or inadequate nutritional intake are inherently more vulnerable to declines in muscle health regardless of which weight-loss strategy is employed. For these populations, the authors advocate a risk-stratified approach: baseline assessment and longitudinal monitoring of muscle strength and physical performance, attention to the rate of weight loss, and individualized nutritional support, whereas patients with preserved muscle reserve can generally be followed with routine clinical care.

The practical prescriptions that follow are grounded in established evidence rather than speculation. Adequate dietary protein intake, tailored to age, renal function, and nutritional status, should accompany pharmacological weight loss, and progressive resistance exercise should be regarded as an essential component of obesity treatment rather than an optional adjunct, complemented by aerobic activity to optimize cardiometabolic health. These recommendations align with current obesity guidelines and with studies showing that resistance training attenuates lean mass loss while improving muscle strength and physical performance during intentional weight loss. The authors also situate the muscle debate within the broader risk-benefit calculus of incretin therapy, noting that semaglutide has been shown to reduce major cardiovascular events in people with overweight or obesity and established cardiovascular disease, and that recent phase 3 data demonstrate benefits in metabolic dysfunction-associated steatohepatitis. Emerging analyses suggest these cardiovascular gains may not be fully explained by the magnitude of weight loss, pointing to anti-inflammatory and direct receptor-mediated effects that extend beyond adiposity reduction.

Significant knowledge gaps remain, and the perspective is candid about them. Long-term data extending beyond the duration of current clinical trials are limited, and the effects of incretin therapies in people with established sarcopenic obesity have barely been studied. The authors call for future research to prioritize muscle quality and function over lean mass alone, to establish standardized definitions of clinically meaningful muscle loss, and to test whether combining incretin drugs with resistance exercise, nutritional optimization, and emerging anabolic agents targeting the myostatin-activin signaling pathway can further optimize body composition and functional outcomes in high-risk groups. Skeletal muscle is also an endocrine organ, releasing myokines that regulate glucose and energy metabolism across organs, so substantial loss of functional muscle tissue could carry metabolic consequences beyond strength and mobility, a consideration that keeps the question scientifically live even as the clinical picture looks reassuring.

The conceptual shift the authors propose is ultimately about how medicine should judge success in obesity treatment. The field has already moved from counting kilograms to analyzing body composition, and the next step, they argue, is to focus on patient-centered outcomes: whether treatment leaves people healthier, stronger, and more functional. By that standard, the available evidence suggests that incretin therapies are restoring physiology rather than eroding it, preferentially removing the fat that drives disease while preserving, and possibly improving, the quality of the muscle that remains. Rather than viewing every kilogram of lean tissue lost as evidence of harm, clinicians should ask the harder and more meaningful question of whether patients can move better, live longer, and feel healthier, and on current evidence, the answer for most appears to be yes, provided that protein intake, resistance exercise, and vigilant monitoring of vulnerable patients remain part of the prescription.

Subject of Research: Body composition changes and sarcopenia risk during incretin-based obesity therapy

Article Title: Losing Muscle or Restoring Physiology? Reframing the Incretin Therapy Sarcopenia Concern

Article References: Koufakis, T., Tentolouris, A., Karakasis, P., Popovic, D. S., & Patoulias, D. (2026). Losing Muscle or Restoring Physiology? Reframing the Incretin Therapy Sarcopenia Concern. Advances in Therapy. https://doi.org/10.1007/s12325-026-03804-z

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03804-z

Keywords: incretin therapy, semaglutide, tirzepatide, obesity, sarcopenia, lean body mass, body composition, skeletal muscle, resistance exercise, muscle quality, bariatric surgery, cardiometabolic health